

¹Michigan State University, ²Harvard University, ³Frontier Science, ⁴Stellenbosch University, ⁵University of Witwatersrand, ⁶FHI360, ⁷NIH/NIMH, ⁸NIH/NIAID, ⁹NIH/NICHD, ¹⁰Dartmouth University

Presentation TUPEB117









scent AIDS Clinical Trials

	HIV (N = 246)	HEU (N = 183)	HUU (N = 182)	P-value *
Male (%)	45.1	51.9	46.2	0.35
Black African (%)	98.4	96.2	82.4	<.001
Age (mean, sd)	7.1 (1.2)	7.3 (1.6)	7.3 (1.5)	0.96
WHO BMI z-score (median; interq. range)	-0.2 (8,.4)	0 (6, .7)	-0.1 (7, .6)	0.08
MICS disability (median; interq. range)	5 (0,10)	0 (0,10)	0 (0,10)	<.001
Caregiver (Cgv) is biol. mother (%)	85	99	100	<.001
Cgv completed high school (%)	29.7	30.6	36.8	0.09
Receives social	23.6	26.9	14.8	0.02

www.PosterPresentations.com

leuropsychological performance in African children with HIV enrolled in a multi-site anti-retroviral clinical trial is poorer than non-infected children at those study sites.

<u>Michael Boivin¹</u>, Miriam Chernoff², Bonnie Zimmer³, Barbara Laughton⁴, Celeste Joyce⁵, Katie McCarthy⁶, Pim Brouwers⁷, Patrick Jean-Philippe⁸, Sonia Lee⁹, Joan Coetzee⁴, Avy Violari⁵, Mark Cotton⁴, Paul Palumbo¹⁰

Conclusions from Years 1 of P1104s

We established the feasibility of obtaining multi-site neuropsychological measures in African children with HIV along with appropriate control comparisons; with significant performance deficits for the HIV group across

Still, significant differences by site for our cognitive test outcomes evidence the importance of considering site-specific contextual and sampling features

Even with early treatment intervention through P1060, the HIV performance deficits demonstrate the need for neuropsychological monitoring and

P1104s children have been assessed for a 2nd time (week 48), are now being assessed for a third time (2/3 completed week 96 assessment as of June, 2016), providing a neuropsychological evaluation at several time points over a two-year period in order to further gauge the brain/behavior

developmental trajectory of early and ongoing pediatric HIV treatment/care

Feasibility/Validity/QA of P1104s

- Between 91.5-95.6% of the cohort children completed all three tests (KABC-II, TOVA, BOT-2) in one day with high overall completion rates (TOVA 95-98%; BOT-2 and KABC close to 100%), and only 3% being invalid (KABC by cohort)
- Only 3% of entered scores were possibly invalid (KABC by cohort), mostly due to out-of-limit or extreme outlier designations. These were queried and have been corrected
- First time a quality assurance plan involving monthly video-taping and review has been implemented in a multi-site neuropsychological study of this sort in African pediatric HIV, with scores averaging above 90% at 5/6

Secondary Study Aim from P1060 "Intent to Treat" analysis: NVP and LPV/r, in HIVinfected children (Year 1)

- In the HIV cohort, the NVP arm had lower median KABC-II Planning and Nonverbal Index scores (by 3 points each, *P*=0.04, 0.05 resp.)
- The NVP arm had lower median BOT-2 standardized scores (by 1.5 points, P=0.03) than the LPVr arm
- No differences between treatment arms on any other KABC-II or TOVA outcomes.

Acknowledging the P1104s Study Leadership Michael Boivin, Ph.D., M.P.H. Protocol Chair: Study Statistician: Miriam Chernoff, Ph.D. Bonnie Zimmer, B.S. Data Manager: NIAID Medical Officer: Patrick Jean-Philippe, M.D. NICHD Medical Officer: Sonia Lee, Ph.D.

NIMH Medical Officer: Pim Brouwers, Ph.D. Clinical Trials Specialists (FHI360): Katie McCarthy, MPH, J.L. Ariansen, MPH

Study Investigators: Paul Palumbo, M.D., Avy Violari, M.D., Mark Cotton, M.D., Barbara Laughton, M.D.

Site Coordinators: Linda Barlow-Mosha, Nasreen Abrahams, Lee Farleigh, Hermien Gous, Portia Kamthunzi, Mutsa Bwakura-Dangarembizi,

Assessment Center Personnel: Agatha Kuteesa, Ssesanga Titus Triks, Mariah Namubiru Kateete

SOP development: Mary Nyakato (University of Chester, UK)

Field Representative: Joan Coetzee, C.P.N. Laboratory Data Coordinator: Brittany White, B.S.